Biohaven Ltd. (NYSE:BHVN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Biohaven Ltd. (NYSE:BHVN) have been given an average recommendation of “Moderate Buy” by the eighteen ratings firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $21.6250.

BHVN has been the subject of several recent research reports. Canaccord Genuity Group initiated coverage on shares of Biohaven in a research note on Monday, April 13th. They issued a “buy” rating and a $21.00 price target for the company. Wall Street Zen raised Biohaven from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Royal Bank Of Canada reduced their price target on Biohaven from $23.00 to $22.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. HC Wainwright reaffirmed a “neutral” rating and issued a $10.00 price target on shares of Biohaven in a research note on Tuesday, May 26th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Biohaven in a research note on Friday, June 26th.

Hedge Funds Weigh In On Biohaven

Hedge funds have recently modified their holdings of the company. Sigma Planning Corp boosted its holdings in shares of Biohaven by 9.2% during the fourth quarter. Sigma Planning Corp now owns 13,613 shares of the company’s stock worth $154,000 after purchasing an additional 1,146 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Biohaven by 113.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after buying an additional 1,268 shares during the period. IFP Advisors Inc grew its position in shares of Biohaven by 55.4% in the 4th quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock worth $46,000 after buying an additional 1,450 shares during the last quarter. Rafferty Asset Management LLC grew its position in shares of Biohaven by 1.3% in the 2nd quarter. Rafferty Asset Management LLC now owns 121,189 shares of the company’s stock worth $1,710,000 after buying an additional 1,503 shares during the last quarter. Finally, ProShare Advisors LLC increased its stake in shares of Biohaven by 10.8% during the fourth quarter. ProShare Advisors LLC now owns 17,138 shares of the company’s stock valued at $193,000 after buying an additional 1,669 shares during the period. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Stock Down 0.2%

Shares of NYSE BHVN opened at $15.93 on Tuesday. The stock has a market capitalization of $2.40 billion, a P/E ratio of -2.81 and a beta of 1.28. Biohaven has a one year low of $7.48 and a one year high of $18.57. The firm’s 50 day simple moving average is $11.38 and its two-hundred day simple moving average is $10.99. The company has a debt-to-equity ratio of 1.87, a current ratio of 7.41 and a quick ratio of 7.41.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). As a group, analysts expect that Biohaven will post -3.1 EPS for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.